Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-02-13
2007-02-13
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S268000
Reexamination Certificate
active
10609670
ABSTRACT:
The present invention is directed to derivatives of gambogic acid and analogs thereof. Exemplary gambogic acid derivatives of the present invention include, among others, derivatives substituted in the C10 and C28 positions of gambogic acid. The present invention also relates to the discovery that certain preferred compounds of the present invention are activators of caspases and inducers of apoptosis. Therefore, the activators of caspases and inducers of apoptosis of this invention can be used to induce cell death in a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
REFERENCES:
patent: 6462041 (2002-10-01), Cai et al.
patent: 6613762 (2003-09-01), Cai et al.
patent: WO 00/44216 (2000-08-01), None
patent: WO 00/45165 (2000-08-01), None
Wiseman, L.R. and Spencer, C.M., “Paclitaxel—An Update of its Use in the Treatment of Metastatic Breast Cancer and Ovarian and Other Gynaecological Cancers,”Drugs&Aging 12:305-334, Adis International Limited (1998).
Written Opinion for International Patent Application No. PCT/US03/20668, 5 pages, mailed Jan. 23, 2006.
Adawadkar, P.D., et al., “Colouring Matters ofGarcinia morella: Part VIII—Morellinol, Dihydromorelloflavone & Morelloflavone-7″-β-glucoside”,Indian J. Chem. 14B:19-21, The Council of Scientific & Industrial Research, New Delhi (1976).
Adjei, A.A., et al., “Synergy of the Protein Famesyltransferase Inhibitor SCH66336 and Cisplatin in Human Cancer Cell Lines,”Clin. Cancer Res. 7:1438-1445, American Association for Cancer Research (May 2001).
Ahmad, S.A., et al., “Gamboge. Part II,”J. Chem. Soc.(C)1:772-779, The Chemical Society (1966).
Almond, J. B., and Cohen, G.M., “The proteasome: a novel target for cancer chemotherapy,”Leukemia 16:433-443, Nature Publishing Group (Apr. 2002).
Asano, J., et al., “Cytotoxic Xanthones forGarcinia hanbury I,” Phytochemistry 41:815-820, Elsevier Science, Ltd. (1996).
Batteux, F., et al., “Gene Therapy of Experimental Autoimmune Thyroiditis by In Vivo Administration of Plasmid DNA Coding for Fas Ligand,”J. Immunol. 162:603-608, The American Association of Immunologists (1999).
Benning, C.M., and Kyprianou, N., “Quinazoline-derived α1-Adrenoceptor Antagonists Induce Prostate Cancer Cell Apoptosis Via an α1-Adrenoreceptor-independent Action,”Cancer Res. 62:597-602, American Association for Cancer Research (Jan. 2002).
Bhat, H.B., et al., “The Colouring Matters ofGarcinia morella: Part V—Isolation of Desoxymorellin & Dihydroisomorallin,”Indian J. Chem. 2:405-410, The Council of Scientific & Industrial Research, New Delhi (1964).
Blanke, C.D., “Celecoxib With Chemotherapy in Colorectal Cancer,”Oncology 16(Suppl. 3):17-21, CMP Healthcare Media Publishing Group (Apr. 2002).
Boirivant, M., et al., “Lamina Propia T Cells in Crohn's Disease and Other Gastrointestinal Inflammation Show Defective CD2 Pathway-Induced Apoptosis,”Gastroenterology 116:557-565, W.B. Saunders Co. (1999).
Calabresi, P., and Chabner, B.A., “Chemotherapy of Neoplastic Diseases: Introduction,” inGoodman&Gilman's The Pharmacological Basis of Therapeutics, Section X, Chapter 51, 9th ed., Wonsiewicz, M.J., and McCurdy, P., eds., McGraw-Hill Health Professions Division, New York, NY, pp. 1225-1287 (1996).
Cao, S-G., et al., “Cytotoxic Caged Tetraprenylated Xanthonoids fromGarcinia gaudichaudii(Guttiferae),”Tetrahedron Lett. 39:3353-3356, Elsevier Science, Ltd. (1998).
Cao, S-G., et al., “Novel Cytotoxic Polyprenylated Xanthonoids fromGarcinia gaudichaudii(Guttiferae),”Tetrahedron 54:10915-10924, Elsevier Science, Ltd. (1998).
Chinnaiyan, A.M., et al., “The inhibition of pro-apoptotic ICE-like proteases enhances HIV replication,”Nat. Med. 3:333-337, Nature Publishing Company (1997).
Coven, T.R., et al., “PUVA-induced lymphocyte apoptosis: Mechanism of action in psoriasis,”Photodermatol. Photoimmunol. Photomed. 15:22-27, Blackwell Publishing (1999).
Delgado, C., et al., “The Uses and Properties of PEG-Linked Proteins,”Crit. Rev. Ther. Drug Carrier Syst. 9:249-304, CRC Press, Inc. (1992).
Friesen, C., et al., “Involvement of the CD95 (APO-1/Fas) receptor/ligand system in drug-induced apoptosis in leukemia cells,”Nat. Med. 2:574-577, Nature Publishing Company (1996).
Giermasz, A., et al., “Potentiating Antitumor Effects of a Combination Therapy with Lovastatin and Butyrate in the Lewis Lung Carcinoma Model in Mice,”Int. J. Cancer 97:746-750, Wiley-Liss, Inc. (Feb. 2002).
Heenan, M., et al., “Methotrexate induces apoptotic cell death in human keratinocytes,”Arch. Dermatol. Res. 290:240-245, Springer-Verlag (1998).
Infante, A.J., et al., “The clinical spectrum in a large kindred with autoimmune lymphoproliferative syndrome caused by a Fas mutation that impairs lymphocyte apoptosis,”J. Pediatr. 133:629-633, Mosby, Inc. (1998).
Kalemkerian, G.P., and Ou, X., “Activity of fenretinide plus chemotherapeutic agents in small-cell lung cancer cell lines,”Cancer Chemother. Pharmacol. 43:145-150, Springer-Verlag (1999).
Kelland, L.R., et al., “Preclinical Antitumor Activity and Pharmacodynamic Studies with the Farnesyl Protein Transferase Inhibitor R115777 in Human Breast Cancer,”Clin. Cancer Res. 7:3544-3550, American Association for Cancer Research (Nov. 2001).
Kyprianou, N., and Benning, C.M., “Supression of Human Prostate Cancer Cell Growth By α1-Adrenoceptor Antagonists Doxazosin and Terazosin via Induction of Apoptosis,”Cancer Res. 60:4550-4555, American Association for Cancer Research (2000).
Leong, Y-W. et al., “Forbesione, a Modified Xanthone fromGarcinia forbesii,”J. Chem. Res. Synop., Issue 8:392-393, The Royal Society of Chemistry (1996).
Lin, L-J., et al., “Isogambogic acid and Isomorellinol fromGarcinia hanburyi,” Magn. Reson. Chem. 31:340-347, John Wiley & Sons, Ltd. (1993).
Liu, W.M., et al., “Thein vitroactivity of the tyrosine kinase inhibitor ST1571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents,”Br. J. Cancer 86:1472-1478, Nature Publishing Group on behalf of Cancer Research UK (May 2002).
López-Hoyos, M., et al., “Regulation of B cell apoptosis by Bcl-2 and Bcl-XLand its role in the development of autoimmune diseases (Review),”Int. J. Mol. Med. 1:475-483, D.A. Spandidos (1998).
Los, M., et al., “Cross-Resistance of CD95- and Drug-Induced Apoptosis as a Consequence of Deficient Activation of Caspases (ICE/Ced-3 Proteases),”Blood 903118-3129, American Society of Hematology (1997).
Lu, G-B., et al., “Isolation and Structure of neo-Gambogic Acid from Gamboge (Garcinia hanburryi),”Yaoxue Xuebao [Acta Pharmaceutica Sinica] 19:636-639, Beijing: Zhongguo yao xue hui (1984).
Lu, G., et al., “Isolation and structure of neo-gambogic acid from gamboge (Garcinia hanburryi),”Chemical Abstracts 102:395, Abstract No. 102:21181z, American Chemical Society (1985).
Motwani, M., et al., “Augmentation of Apoptosis and Tumor Regression by Flavopiridol in the Presence of CPT-11 in Hct116 Colon Cancer Monolayers and Xenografts,”Clin. Cancer Res. 7:4209-4219, American Association for Cancer Research (Dec. 2001).
Ohsako, S., and Elkon, K.B., “Apoptosis in the effector phase of autoimmune diabetes, multiple sclerosis and thyroiditis,”Cell Death Differ. 6:13-21, Stockton Press (1999).
Ollis, W.D., et al., “The Constitution of Gambogic Acid,”Tetrahedron 21:1453-1470, Pergamon Press, Ltd. (1965).
O'Reilly, L.A., and Strasser, A., “Apoptosis and autoimmune disease,”Inflamm. res. 48:5-21, Birkhäuser Verlag (1999).
Ozawa, M., et al., “312-nanometer Ultraviolet B Light (Narrow-Band U
Cai Sui Xiong
Drewe John A.
Kasibhatla Shailaja
Ollis Kristin P.
Sirisoma Nilantha Sudath
Cytovia, Inc.
Solola Taofiq
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Derivatives of gambogic acid and analogs as activators of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Derivatives of gambogic acid and analogs as activators of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of gambogic acid and analogs as activators of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3863648